Health ❯ Pharmaceuticals

Cancer Treatment

Drug Development Prostate Cancer Immunotherapy mRNA Therapies FDA Regulations Clinical Trials mRNA Technology Letrozole Leucovorin Tumor Diseases AI Applications Generic Drugs Lung Cancer Rare Diseases Cancer Vaccine Drug Pipeline Monoclonal Antibodies Keytruda Corporate Ethics Trastuzumab Rezetecan Myelofibrosis Drug Importation Research and Development Autoimmune Diseases Multiple Sclerosis

ImmunityBio Investors Face May 26 Deadline in Securities Class Action Over FDA Ad Rebuke

The case turns on claims that Anktiva promotions misled patients as well as investors.

Lilly to Acquire Ajax Therapeutics in Up to $2.3 Billion Blood Cancer Deal

ImmunityBio Investors Urged to Seek Lead Role in Suit After FDA Rebuke Over Anktiva Ads

Law Firms Urge Telix Investors Ahead of Lead‑Plaintiff Deadline in Securities Class Action

Law Firms Urge Telix Investors To Seek Lead Role by Jan. 9 in Securities Class Action

Telix Securities Class Action Draws Flurry of Investor Notices Ahead of Lead-Plaintiff Deadline

Multiple Firms File Securities Class Actions Against Telix in Indiana Federal Court Over Prostate Cancer Program Disclosures

Recursion Soars on Heavy Volume as Investors Eye CEO’s AI Conference Appearance

Eli Lilly Picks Virginia for $5 Billion Bioconjugate Plant, First of Four New U.S. Sites